MAPT and Alzheimer disease: It can also affect the development of AD by blocking Aβ clearance, accelerating Aβ aggregation, influencing Tau pathology and Tau-mediated neurodegeneration, and damaging synaptic integrity and plasticity (Komai et al., 2024; Strittmatter et al., 1993).